Preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for diseases with high unmet medical needs, today announced that the preclinical data indicating that drug candidate CS585, a novel prostacyclin (IP) receptor agonist, inhibits platelet activation and clot formation up to 24 hours post-administration, has been published in European Heart Journal. The data was presented on August 31st this year at the ESC (European Society of Cardiology) Congress 2024 .The article